|Bid||82.68 x 800|
|Ask||87.90 x 900|
|Day's Range||82.81 - 84.32|
|52 Week Range||62.55 - 101.28|
|Beta (5Y Monthly)||0.71|
|PE Ratio (TTM)||18.55|
|Earnings Date||Oct 30, 2020|
|Forward Dividend & Yield||4.72 (5.62%)|
|Ex-Dividend Date||Oct 14, 2020|
|1y Target Est||109.12|
The big pharma stock is priced so low mainly because investors are worried about AbbVie's growth prospects once top-selling autoimmune disease drug Humira begins to face biosimilar rivals in the U.S. in 2023. Although that's a legitimate concern, it's important to look at the big picture for AbbVie. First of all, Humira's sales will certainly decline significantly but won't evaporate overnight.
In the latest trading session, AbbVie (ABBV) closed at $83.92, marking a -0.5% move from the previous day.
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.